If this was near the start of the LOI i would agree but not at the concluding stage. That can only be tested by waiting a few weeks longer closer to the end of March although that is not an official deadline.
I have no doubt TRX has raised the funds so all this is not helpful at this time. Change might be good depending on the outcome but the timing is wrong so I would vote against it for now if it comes to it. It just creates more instability at the wrong time.
This does not favour existing holders but I don't see anyone selling in fact we might see buyers. Those here calling for change will nicely walk away if 201 failed so I don't think this helps the situation at this time.
As I said numerous times I would have waited until 31st March but I would think the outcome of the merger would be much sooner. If that failed then I would have pushed for changes as the damage would be at a point where it could not get worse.
I see it as a huge positive if it is Adam stepping forward but I don't want another Suzy or two. No time for apprentices and those trying to get a cheap salary and options.
Adam Hargreaves
Dr Adam Hargreaves is the founder of PathCelerate Limited, a contract research pharmaceutical efficacy and safety company. Spanning a 20-year career, he previously worked for AstraZeneca, and has interests and skills in preclinical and translational small molecule, biologic, and RNA-based pharmaceuticals. PathCelerate has provided preclinical and clinical drug discovery and development assistance to a number of global pharmaceutical companies, in addition to a wide and diverse range of small- and medium-sized biotechnology and medical device firms; assisting in the generation of numerous Investigational New Drug and Clinical Trial Application submissions.
Adam is a Fellow of the Royal College of Pathologists and is a board-certified Diplomate of the American College of Veterinary Pathology. His PhD research encompassed oncology medicine safety and he has held posts including President of the British Society of Toxicologic Pathology and Visiting Professor at the University of Surrey, where he lectures in pharmaceutical efficacy and safety. He is a keen investor in small-cap drug discovery and biotechnology AIM stocks, and takes a particular interest in how such companies attract both retail and institutional investment via portfolio expansion and pertinent news flow.
Look Adam on the BOD would be a dream come true for everyone and even better than the 201 deal.
If that is the case then shareholders have done well and we can finally get to where we should be.
I really hope it is Adam as he has a business mind and all the knowledge. His focus will be driving the SP forward not the long term bull chit we hear every year forever.
Not important how deep I am. I hold and I have not sold because I see value at this price. What will make it worse for me is if I see this go up 500% plus next week or soon.
I fully expect the merger to be successful and 201 to be signed soon after therefore I expect a huge rise from this market cap.
Suzy confirmed that LOI is in place and if it was not they would have to announce. Add that to the fact they spent 4 months formally working on the merger and many months before that. Highly unlikely to fail imo. If it goes ahead the rise from here could really be anything from 300-1000% imo given the current market cap.
You also don't update a website with your profiles if the news is about to be bad. Figure it out. What an opportunity to buy but not much shares left and slowly we creep up now.
LOI last time took this to 65p with 65 million shares but with not funding no lab no CLX.
Now we have all that but 130 million shares.
We can rise like HE1 up 500% as the milestones will be huge relative to the market cap. Also the extra 2 million means it is highly likely we get a preclinical deal before any placing in the future and that would be 10/20 million upfront.
Likely the final build up before merger news announced.
A gifted leader, Ken’s high standards in science and business operations serve as an example and impetus to others and to the formation of successful new biotechnology companies. Ken has successfully raised more than $1 billion of capital to support translational research and to enable new biotechnology companies to move from scientific concepts to commercialized products.
Well Adam was thinking 10/20 million upfront for CLX alone. The data and science for that is very strong. Don't need peer review at this stage it can be sold.
Same as the other compounds. Full patent life positive early results can fetch a few millions each.
IF the assets are worth more than 20/30 million in total then why not list for a takeover?
These guys are not getting anywhere so might as well sell the business. If someone can go inside and arrange for this to happen that would be good.
Sell lab, CLX and if they can get 201 over the line and sign the deal list the business for sale. Might then get 30/40 million.
The strategy and the lab is fine but they should not spend anymore until they deliver big. How else would you develop early stage compounds or do you just keep 201, 301 and 401 and nothing else. You can out license projects but this will cost more. Also revenue is needed to attract large investments.
The execution is poor. We should be more than 20p so with good news especially 201 then we can rise big. Officially they have projected until H2 in 2025 not September 2024 but if 201 completes with some decent lab contracts it will be much longer. Porky claims to follow the broker report but takes out what he wants to fit his agenda.
Based on assets we should easily be 20p plus.
I would give it until the end of March to see what they can do as I expect 201 to complete. Pointless if you are invested and moaning on here and dragging the price even lower only for the other traders on here to buy much cheaper whilst you lose money.
News will come. Changing them at this stage means we only go backwards. I would say by the end of March they would have had enough of a chance.
Again most here are not invested or have lost most of the money over the years so a different agenda.
I agree that a poor job has been done so far in terms of delivery. Not denying it. I just think if we get a new BOD then it will need at least 3-5 dilutions to see any real value. Don't assume instant success as it will take a considerable amount of time to understand the projects, build connections and modify the strategy. Look at APTAMER as an example and if another placing happens in that stock it will likely be far lower than where it is now.
Like HE1 by getting 201 over the line and getting out other news this can turn around significantly. The additional cash will give us at least 2 years worth of capital without lab revenue or other deals. I might be down but the only way I see a return is if this BOD delivers and only if they deliver. Anyone else unless it is Adam then basically existing holders will be washed away. The company could succeed under new management but it will need additional money and time so not great for us.
I understand the merger needs to be completed by the end of March. The fact that it has been ongoing must mean it will likely succeed so no harm done waiting until the end of March. If no progress is made then I would have nothing more to say.
At this market cap we have it all to gain and with cash for 12 months I would expect some positive news. 401 is also due to complete this year and CLX news will come good or bad but at this market cap I fancy my chances of this going back up.
Hi Neil,
The 900 pounds investment. How much is it worth now? Probably a few pounds? Much of that was handled by the old BOD which led to older patents therefore making it more difficult getting a deal although handled poorly by TRX so far.
I think 201 changes everything here. Much depends on it. The extra 2 million gives more time for a big deal for one of the newer compounds which is where the real value will lie. With milestones and payments this would lead to a strong recovered like HE1 but it is needed. A much higher share price means lower dilution if one is needed in the future. Without it then we would drift a bit or stay where we are which is not what shareholders want.
I think the deadline is at the end of March but I don't see it going that far. News soon and likely a positive given the time taken proceeding with the merger. More news with that relating to CLX and contracts is very likely.
Most here on this BB are not invested.
Freddy,
Not everyone can drive. Unless it is Adam then pointless imo as it will send us backwards.
Most LTH are down here but no reason why this cannot get to at least 15p then we can see if it is worth holding or not depending on how good the news is.